Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4868 - Updated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Clinical Research


Junji Tsurutani


Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367


J. Tsurutani1, T. Doi2, H. Iwata3, S. Takahashi4, S. Modi5, K. Tamura6, K. Shitara7, H. Taniguchi8, S. Taira9, B. Li10, A. Shimomura11, Y. Sato12, K. Akiyama12, Y. Fujisaki12, C. Lee13, A. Yver14, K. Nakagawa1

Author affiliations

  • 1 Depertment Of Oncology, Kindai University School of Medicine, 577-8502 - Osaka/JP
  • 2 Department Of Experimental Therapeutics, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 3 Breast Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 4 Department Of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 135-8550 - Tokyo/JP
  • 5 Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 6 Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 7 Gastroenterology And Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 8 Department Of Clinical Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 9 Department Of Medical Oncology, Cancer Institute Hospital of JFCR, 135-8550 - Tokyo/JP
  • 10 Department Of Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 11 Department Of Breast And Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 12 Oncology Clinical Development Department, DAIICHI SANKYO CO., LTD., 140-8710 - Tokyo/JP
  • 13 Global Oncology R&d, Daiichi Sankyo, Inc., 08837 - Edison/US
  • 14 Global Oncology R&d, Daiichi Sankyo Pharma Development, 8837 - Edison/US


Abstract 4868


DS-8201a is a HER2 targeting antibody-drug conjugate of high drug to antibody ratio (7 to 8) with a novel linker and topoisomerase I inhibitor. In preclinical studies, DS-8201a showed a broad antitumor spectrum, including efficacy against low HER2 expressing breast cancer (BC) and HER2 expressing non-gastric and non-breast cancers. The current phase 1 trial includes dose escalation (Part 1) and expansion (Part 2) including BC, gastric cancer (GC) and other HER2 expressing solid tumors.


Part 1 used a mCRM to identify the recommended dose in patients (pts) with BC or GC. Part 2 was designed to evaluate the safety and efficacy in 4 expansion cohorts: HER2 positive BC, HER2 positive GC, low HER2 expressing BC, and other solid tumors expressing HER2. HER2 expression was determined by IHC, FISH, NGS or other platforms. Adverse events (AEs), objective response rate (ORR), and disease control rate (DCR: CR + PR + SD) were assessed.


Twenty four pts in Part 1 and 113 pts in Part 2 were enrolled. 24 of 113 pts were HER2 expressing solid tumors other than BC and GC. DS-8201a was administered up to 8.0 mg/kg in Part 1, and dose level of 6.4 mg/kg IV every 3 weeks was chosen. DLTs were not observed in the study. In the updated Part 1 results, confirmed ORR was 35%, DCR was 91% (BC: 88%, GC: 100%), and the median duration of treatment was ≥32 weeks in heavily pretreated BC and GC pts. Non-BC and non-GC cohort consists of 11 CRC, 5 NSCLC, 4 salivary gland, 2 Paget’s disease, 1 cholangiocarcinoma and 1 esophageal cancer. ORR including under confirmation and DCR were 33% and 91%, respectively in evaluable 12 pts. Two out of 5 evaluable pts with CRC and 2 out of 4 evaluable pts with salivary gland achieved PRs. Of all pts in this phase 1 study, the most common AEs of any grades were nausea (≥Gr1 60%; ≥Gr3 2%), decreased appetite (≥Gr1 55%; ≥Gr3 4%), vomiting (≥Gr1 30%; ≥Gr3 0%) and platelet count decreased (≥Gr1 30%; ≥Gr3 9%). Updated phase 1 results will be presented.


DS-8201a was well tolerated and is remarkably active in pts with heavily pretreated HER2 expressing BC and GC with durable disease control. Promising efficacy in HER2 expressing other tumors was observed and warrants further investigation.

Clinical trial identification


Legal entity responsible for the study

Daiichi Sankyo CO., LTD.


Daiichi Sankyo CO., LTD.


J. Tsurutani: Paid honoraria directly by Eisai, Kyowa Hakko Kirin, Chugai, AstraZeneca, Novartis, Taiho. Paid for any consulting or advisory role by Novartis, Daiichi Sankyo, MSD, Lilly, Roche. Conducted research project funded by Daiich Sankyo, Roche, Lilly, MSD. T. Doi: Paid for consulting by Lilly, Chugai, Kyowa, Behringer, Novartis, MSD, Daiichi Sankyo, Amgen. Conducted study funded by Taiho, Novartis, Merck, Astellas, MSD, Janssen, Boehringer, Takeda, Pfizer, Lilly, Sumitomo, Chugai, Bayer, Kyowa, Daiichi Sankyo. H. Iwata: Paid honoraria directly by Daiichi Sankyo, Chugai, AstraZeneca. Paid for consulting or advisory role by Daiich Sankyo and Pfizer. Conducted research project funded by Daiich Sankyo, Chugai, AstraZeneca, Pfizer, Novartis, Eisai, MSD, Lilly. S. Takahashi: Paid honoraria directly by Eisai, Astellas, Taiho, Bayer, Daiichi Sankyo, Pfizer, AstraZeneca. Paid for consulting or advisory role by Chugai Astellas. Conducted study funded by Eisai, Chugai, MSD, Lilly, AstraZeneca, Novartis, Taiho, Daiichi Sankyo. K. Tamura: Conducted study funded by Daiichisankyo, MSD, pfizer, AstraZeneca. K. Shitara: Paid for consulting or advisory role by Chugai Pharma, Takeda, Bayer, Lilly, Bristol-Myers, Squibb. Conducted study funded by Dainippon Sumitomo Pharma, Lilly, MSD, Sanofi, Daiichi Sankyo, Taiho Pharmaceutical, Bayer, Chugai. H. Taniguchi: Honoraria for speaking or writing engagements from Takeda, Chugai, Merck Serono, Taiho, Bayer, Lilly, Yakult. Financial support for clinical trials or research found by Otsuka, Boehringer Ingelheim, MSD Oncology, Takeda. B. Li: Consulting and/or Advisory Board for Genentech, ThermoFisher Scientific, Biosceptre Australia. Principle Investigator of clinical trials supported by Genentech, AstraZeneca, BioMedValley. A. Shimomura: Conducted study funded by AstraZeneca. Y. Sato, K. Akiyama, Y. Fujisaki, C. Lee, A. Yver: Employee of Daiichi Sankyo. K. Nakagawa: Paid for any consulting or advisory role by Astellas. Ono, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo. Conducted study funded by GlaxoSmithKline, Yakult, AstraZeneca, PAREXEL, Kyowa Hakko, Otsuka, Pfizer, Astellas, Daiichi Sankyo. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.